ICYMI: bit.ly/4heAnqH Healthcare expenditures decreased substantially after bariatric surgery for patients with #diabetes. Medication expenses decreased by more than 50% in the 5 years post surgery, with no significant differences between Roux-en-Y gastric bypass

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes pubmed.ncbi.nlm.nih.gov/39882599/

What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery? pubmed.ncbi.nlm.nih.gov/39888611/

Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study pubmed.ncbi.nlm.nih.gov/39903478/

In Diabetes Care, a research journal of the ADA 🌟 today: In ARMMS-T2D trial, bariatric surgery produced sustained weight loss & improved quality of life (general health, physical functioning, vitality, etc ) in patients with diabetes & obesity compared with medical therapy up to 12 yrs diabetesjournals.org/care/article-a…

Digital Mindfulness Training for Burnout Reduction in Physicians: Clinician-Driven Approach pubmed.ncbi.nlm.nih.gov/39854701/

Physician Burnout is Real. Help Us Understand and Prevent it! My colleagues at Brown University are recruiting physicians for a study of burnout. See flyer below.

From the Annals ‘Spotlight on 2024’ collection: A target trial emulation study found #bupropion was consistently associated with the least weight gain among 8 first-line #antidepressant treatments. bit.ly/4hQ8e9o

"We are at risk of designing our obesity strategy around a single drug rather than developing a holistic weight management strategy." A look at the rise to prominence of Tirzepatide (Mounjaro) and its implications bmj.com/content/388/bm…

Most viewed in the last 7 days from JAMA Surgery: Ten-year RCT data show similar long-term weight loss outcomes for roux-en-y gastric bypass and sleeve gastrectomy, with fewer conversions and better reflux control favoring roux-en-y gastric bypass. ja.ma/3QJfcBe

Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes - neoadjuvant semaglutide did not confer benefits for weight loss, diabetes remission, or MBS safety. MBS weight loss significantly less with pre-op semaglutide .jamanetwork.com/journals/jamas…

In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment JAMA Neurology jamanetwork.com/journals/jaman… #Alzheimersdisease #T2D

Unifying Efforts to Empower Equitable Obesity Care: Synopsis of an American College of Physicians and Council of Subspecialty Societies Summit acpjournals.org/doi/10.7326/AN…

Towards optimal use of GLP-1 medicines for enhancing pregnancy outcomes jamanetwork.com/journals/jamac…

Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States: A Population-Based Cohort Study acpjournals.org/doi/10.7326/AN…

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system pubmed.ncbi.nlm.nih.gov/40285721/

Between 2021 and 2024, #semaglutide and #tirzepatide prescriptions in Epic-affiliated health care systems increased slightly but remained limited, with only 3% of eligible patients receiving them. ja.ma/434WUBr

Leveraging Real-World Evidence to Assess Benefits and Risks of GLP-1-Based Therapies - NEXT WEEK - NIDDK Workshop - Don't Miss It! niddk.nih.gov/news/meetings-… via NIDDK

Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to U.S. FDA for an indication to use #tirzepatide (Zepbound) in treating heart failure – specifically for #HFpEF. conscienhealth.org/2025/05/lilly-…

Over a long-term follow-up, patients undergoing gastric bypass exhibited a lower rate of MACE compared to those with sleeve gastrectomy. ja.ma/4k347Yu